1.Evaluation of GRADE Clinical Research Evidence of Chinese Patent Medicine Combined with Western Medicine in Treatment of Hypertension with Dyslipidemia
Jiaheng WANG ; Yukun LI ; Liangyu CUI ; Yilan ZHENG ; Zhiwei ZHAO ; Cong REN ; Tianyue JING ; Tong YIN ; Liying WANG ; Xuejie HAN
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(10):95-105
ObjectiveTo evaluate the effect of antihypertensive and lipid-regulating Chinese patent medicine combined with conventional Western medicine in the treatment of hypertension with dyslipidemia. To carry out the evidence synthesis of clinical research and provide evidence-based evidence support for clinical decision-making. MethodThe databases including China National Knowledge Infrastructure (CNKI),Wanfang Data Knowledge Service Platform (WF),VIP,SinoMed,Embase,PubMed,Web of Science (WOS),and the Cochrane Library were searched for randomized controlled trials (RCT) of all listed Chinese patent medicines in the treatment of hypertension with dyslipidemia from the establishment of the databases to April 15,2023. The literature was screened and extracted,and the risk of bias tool 2.0 (RoB2) was used to assess the quality and risk of bias of the methodology. Revman 5.4.1 software was used to analyze the outcome indicators. Grading of Recommendations Assessment,Development and Evaluation (GRADE) was applied to assess the quality of evidence formed by clinical research data. The inclusion and recommendation of Chinese patent medicines in the National Drug Catalogue for Basic Medical Insurance,Work-related Injury Insurance and Maternity Insurance (2022) and domestic guidelines and consensus were searched to form a bubble chart. ResultA total of 15 studies were included. The evaluation of the methodological quality of each study showed that the risk of bias stemmed from the lack of blinding and allocation concealment,and low sample size. The comprehensive analysis of clinical studies showed that Dengzhan Shengmai capsules combined with rosuvastatin and amlodipine besylate,Yindan Xinnaotong capsules combined with simvastatin and levamlodipine tablets,Xiaoshuan Tongluo capsules combined with nifedipine controlled release tablets and pravastatin sodium tablets,Xinshubao capsules combined with atorvastatin calcium tablets and irbesartan,Wenyading capsules combined with enalapril,and Jiangzhining tablets combined with conventional Western medicines were all superior to conventional Western medicines used in the control group in improving systolic blood pressure (SBP),diastolic blood pressure (DBP),cholesterol (TC),triglyceride (TG),low density lipoprotein cholesterol (LDL-C),and high density lipoprotein cholesterol (HDL-C). There was no significant difference in the incidence of adverse reactions between the two groups. The GRADE evaluation of the main outcome indicators showed that the evidence quality of SBP and incidence of adverse reactions was graded as B,that of DBP as C,and that of total TC,TG,LDL-C,and HDL-C as D. The evaluation of Chinese patent medicines covered by medical insurance and recommended by guidelines and consensus showed that Yindan Xinnaotong soft capsules,Dengzhan Shengmai capsules and Xiaoshuan Tongluo capsules belonged to class B drugs of medical insurance,and were recommended for 7,6 and 3 times in the guidelines and consensus,respectively. ConclusionCompared with simple medicine treatment,Chinese patent medicine combined with conventional Western medicine has more advantages in improving blood pressure and blood lipid,and shows higher safety. Among them,Yindan Xinnaotong soft capsules,Dengzhan Shengmai capsules and Xiaoshuan Tongluo capsules have stronger clinical applicability and economy. All the trials included in this article adhered to the principle of randomization and reported the outcome measures. However,the quality of evidence in related clinical studies was low. In terms of trial design,large-sample,multi-center,blinded randomized controlled trials based on the consolidated standards of reporting trials (CONSORT) statement are still needed for comprehensive trial designs and reporting,to further improve the GRADE quality evaluation and guideline formulation under the guidance of evidence-based medicine,so as to provide higher quality evidence-based research evidence for clinical decision-making.
2.Evaluation of Simulated Weightlessness Model of Hindlimb Unloading Miniature Pigs and Their Tissue Damage
Yingxin TU ; Yilan JI ; Fei WANG ; Dongming YANG ; Dongdong WANG ; Zhixin SUN ; Yuexin DAI ; Yanji WANG ; KAN GUANGHAN ; Bin WU ; Deming ZHAO ; Lifeng YANG
Laboratory Animal and Comparative Medicine 2024;44(5):475-486
Objective To establish a weightlessness simulation animal model using miniature pigs, leveraging the characteristic of multiple systems’ tissue structures and functions similar to those of humans, and to observe pathophysiological changes, providing a new method for aerospace research. Methods Nine standard-grade miniature pigs were selected and randomly divided into an experimental group (n=7) and a control group (n=2). The experimental group was fixed using customized metal cages, with canvas slings suspending their hind limbs off the ground, and the body positioned at a -20° angle relative to the ground to simulate unloading for 30 days (24 hours a day). Data on body weight, blood volume, and blood biochemistry indicators were collected at different time points for statistical analysis of basic physiological changes. After the experiment, the miniature pigs were euthanized and tissue samples were collected for histopathological observation of the cardiovascular, skeletal and muscle systems HE and Masson staining. Statistical analysis was also conducted on the thickness of arterial vessels and the diameter of skeletal muscle fibers. Additionally, western blotting was employed to detect the expression levels of skeletal muscle atrophy-related proteins, including muscle-specific RING finger protein 1 (MuRf-1) and muscle atrophy F-box (MAFbx, as known as Atrogin-1), while immunohistochemistry was used to detect the expression of glial fibrillary acidic protein (GFAP), an indicator of astrocyte activation in the brain, reflecting the pathophysiological functional changes across systems. Results After hindlimb unloading, the experimental group showed significant decreases in body weight (P<0.001) and blood volume (P<0.01). During the experiment, hemoglobin, hematocrit, and red blood cell count levels significantly decreased (P<0.05) but gradually recovered. The expression levels of alanine aminotransferase and γ-glutamyltransferase initially decreased (P<0.05) before rebounding, while albumin significantly decreased (P<0.001) and globulin significantly increased (P<0.01). Creatinine significantly decreased (P<0.05). The average diameter of gastrocnemius muscle fibers in the experimental group significantly shortened (P<0.05), with a leftward shift in the distribution of muscle fiber diameters and an increase in small-diameter muscle fibers. Simultaneously, Atrogin-1 expression in the gastrocnemius and paravertebral muscles significantly increased (P<0.05). These changes are generally consistent with the effects of weightlessness on humans and animals in space. Furthermore, degenerative changes were observed in some neurons of the cortical parietal lobe, frontal lobe, and hippocampal regions of the experimental group, with a slight reduction in the number of Purkinje cells in the cerebellar region, and a significant enhancement of GFAP-positive signals in the hippocampal area (P<0.05). Conclusion Miniature pigs subjected to a -20° angle hind limb unloading for 30 days maybe serve as a new animal model for simulating weightlessness, applicable to related aerospace research.
3.Interpretation for group standard of Management Norms for Human Caring of Outpatients
Shujie GUO ; Baoyun SONG ; Hongmei ZHANG ; Yilan LIU ; Yanming DING ; Zuyu TANG ; Hong LI ; Huiling LI ; Hongzhen XIE ; Yinglan LI ; Baohua LI ; Ruiying YU ; Chuang LI ; Haixin ZHANG ; Yanjin LIU ; Pingfan ZHAO ; Huiling CHEN ; Chunyan GUAN ; Bing SONG ; Guohua LIU
Chinese Journal of Hospital Administration 2024;40(6):419-425
Outpatient humanistic care refered to providing a full process of caring medical services to outpatients. In order to standardize the human caring services for outpatients in medical institutions, promote the comprehensive service level of outpatient services, and improve the patient′s medical experience, Chinese Association for Life Care issued the group standard of Management Norms for Human caring of Outpatients in April 2023. This standard clarified the relevant terms and definitions of human caring for outpatients, specified the basic requirements for human caring, the humanistic quality and care responsibilities of outpatient staff, the outpatient care environment and facilities, the outpatient care process and measures, and quality management. It designed standardized and personalized full process care service norms, providing references for medical institutions at all levels to promote the development of human caring for outpatients.
4.Progress on factors affecting gastrointestinal function and drug protection in high altitude hypoxia environment
Junfei CHENG ; Anpeng ZHAO ; Yilan ZHAO ; Zihan WANG ; Wenbin LI ; Rong WANG
Journal of Pharmaceutical Practice 2023;41(11):648-653
Due to factors such as low pressure, low oxygen and cold in the plateau environment, people who enter the plateau rapidly are susceptible to digestive system diseases, such as upper abdominal pain, loss of appetite, nausea and vomiting and other gastrointestinal dysfunction, which seriously affect the health and work ability of people who enter the plateau rapidly. The gastrointestinal dysfunction caused by the rapid advance to the plateau is mainly reflected in three aspects: gastrointestinal motility dysfunction, impaired mucosal barrier function, and intestinal flora imbalance. At present, the pathogenesis of gastrointestinal dysfunction is still not very clear, and there are fewer drugs for targeted prevention and treatment. Gastrointestinal hormones, oxygen free radicals, inflammatory factors, intestinal flora and other factors, as well as the protective effects of related drugs were reviewed in this paper to provide treatment options and theoretical basis for the prevention and treatment of the gastrointestinal emergency response caused by entering the plateau.
5.Application effect of information platform based on Internet of Things in screening and management of chronic obstructive pulmonary disease
Xingru ZHAO ; Yilan ZHAO ; Zhiwei XU ; Yunxia AN ; Xiaoju ZHANG ; Zhiping GUO ; Linqi DIAO
Chinese Journal of Health Management 2023;17(5):350-355
Objective:To analyze the application effect of the information platform based on the Internet of Things (IoT) in the screening and management of patients with chronic obstructive pulmonary disease (COPD).Methods:In this cross-sectional study, 151 062 residents who participated in the screening in the districts covered by 33 general hospitals and 289 primary medical institutions within the framework of Henan Provincial Center for COPD Prevention and Treatment from November 2021 to October 2022 were included as the subjects. Spirometer based on the IoT was used to conduct pulmonary function tests for subjects who scored 16 points or more with COPD Screening Questionnaire (COPD-SQ), and the subjects were evaluated and managed through the structured electronic data in the information platform. The distribution characteristics and follow-up of the subjects and COPD patients were described and the application effect of this strategy in patients screening and management was analyzed.Results:A total of 151 062 residents with complete basic information in the information platform completed the questionnaire. High-risk population of COPD accounted for 26.5% (40 042/151 062) of the population who received the questionnaire screening, and more than 50% had respiratory symptoms, such as chronic cough (59.4%), or shortness of breath (77.6%). The proportion of high-risk population increased with age, especially after 50 years old. Compared with non-smokers, the proportion of high-risk group was significantly higher (77.1% vs 16.4%) in the group with smoking index over 600. Biofuel exposure (61.3% vs 22.1%) and family history of respiratory diseases (64.2% vs 22.6%) were associated with an increased proportion of high-risk groups, with statistically significant differences ( P<0.001). 5 268 patients were diagnosed with COPD by pulmonary function tests, and the prevalence of COPD in high-risk groups was 27.8% (5 268/18 965), the prevalence rate of male was 34.0% (3 942/11 588), which was higher than that of female 18.0% (1 326/7 377). 2 950 patients (56.0%) completed at least one follow-up of symptom questionnaire and 510 patients (9.7%) completed more than one follow-up of pulmonary function test. Conclusion:The screening and management strategy of COPD based on the IoT and information technology can improve the efficiency of COPD screening, and improve the status quo of under-diagnosis and discontinuous follow-up of COPD.
6.Immune response after vaccination using inactivated vaccine for coronavirus disease 2019.
Ya SUN ; Haonan KANG ; Yilan ZHAO ; Kai CUI ; Xuan WU ; Shaohui HUANG ; Chaofan LIANG ; Wenqiang WANG ; Huixia CAO ; Xiaoju ZHANG ; Fengmin SHAO
Chinese Medical Journal 2023;136(12):1497-1499
7.Establishment and preliminary application of dual fluorescent quantitative PCR for detection of RV and CAV2
Jian LIU ; Yaping GUI ; Yilan BAI ; Luming XIA ; Xiaoying ZHU ; Xianchao YANG ; Tiangusheng TAO ; Congsheng TANG ; Yujie ZHANG ; Jian WANG ; Hongjin ZHAO
Journal of Public Health and Preventive Medicine 2023;34(3):33-37
Objective To investigate the shedding of CAV2-ΔE3-CGS after immunization and the background of canine adenovirus (CAV) infection, and to establish a dual fluorescent quantitative PCR detection method for rabies virus (RV) and canine adenovirus type 2 (CAV2). Methods A dual fluorescent quantitative PCR detection method was established by designing specific primers and probes for E1 gene of CAV and G gene of RV for the detection of CAV2-ΔE3-CGS. Oral swabs, anal swabs and environmental samples of stray dogs from experimental animal farm and dog detention center were tested. Results The standard curves generated by this method were Y=-3.351 × logX + 44.895, R2 = .999 and Y=-3.413 × logX + 45.192, R2=0.996, respectively. The linear relationships were good, and the minimum detection limits were both 102 copies/μL. CAV2-ΔE3-CGS was not detected in experimental animal farm. CAV was detected in dog detention center, and the positive rates were 5.88% (5/85) in oral swabs, 8.24% (7/85) in anal swabs, and 4% (1/25) in environmental samples. Conclusion The dual fluorescent quantitative PCR method can be used for the detection of CAV2-ΔE3-CGS after immunization and the investigation of CAV infection. The present study has shown that no CAV2-ΔE3-CGS has been detected after immunization and CAV infection rate of stay dogs is low in Shanghai. CAV2-ΔE3-CGS oral immunization meets requirement and is applicable.
8.A multicenter survey on the current status of human caring in hospital wards in China
Yilan LIU ; Fengjian ZHANG ; Xinjuan WU ; Yinglan LI ; Deying HU ; Shengxiu ZHAO ; Yanjin LIU ; Gendi LU ; Dongmei DAI ; Chaoyan XU ; Liqing YUE ; Bilong FENG ; Rong XU ; Yanli WANG ; Adan FU ; Li GOU ; Xiaoping LOU ; Li YANG ; Xinman DOU ; Huijuan SONG ; Xiuli LI ; Yi LI ; Yulan XU ; Liping TAN ; Liu HU ; Xiaodong NING
Chinese Journal of Hospital Administration 2023;39(10):774-780
Objective:To explore the current situation of nursing human caring in hospital wards and analyze its influencing factors, so as to facilitate the development of nursing human caring practice.Methods:From July to November 2022, a total of 107 hospitals were surveyed through stratified convenience sampling method, and 4 072 ward nursing managers were recruited to finish the general information questionnaire and the ward nursing human caring status questionnaire. The general information included the region, class and type of the hospital, etc. The ward nursing human caring status questionnaire included 38 items in 5 dimensions of nursing human caring system and process, humanistic quality and training of nursing staff, humanistic environment and facilities, human caring procedures and measures, and human caring quality evaluation and improvement, with a full score of 190 points. Descriptive statistics were used to analyze the general data, independent samples t-test, ANOVA and correlation analysis were used to analyze the factors influencing the current status of nursing human caring in the ward, while multiple linear regression analysis was used to conduct a multivariate analysis. Results:The score of nursing human caring in hospital wards was 156.91±27.78. Whether the hospital had carried out nursing human caring pilot(demonstration) wards, whether the ward had previously been a hospital nursing human caring pilot(demonstration) nursing unit, the type of ward, and whether nursing managers had participated in human caring training were the influencing factors of the implication of nursing humanistic caring in wards( P<0.05). Conclusions:The practice of nursing human caring in hospital wards is at a good level, but needs to be further strengthened. Nursing managers should take systematically strategies to promote the development of nursing human caring practice.
9.Efficacy and Safety of Peficitinib for Treating Rheumatoid Arthritis :A Systematic Review
Xin LIU ; Changjing XU ; Xiaoyan ZHONG ; Danjie ZHAO ; Bin YU ; Yilan HUANG
China Pharmacy 2020;31(7):859-864
OBJECTIVE:To systematically evaluate the efficacy and safety of pe ficitinib for treating rheumatoid arthritis (RA),and to provide evidence-based reference for the clinical treatment of RA. METHODS :Retrieved from PubMed ,Embase, The Cochrane Library ,CJFD,VIP and Wanfang database during from their establishment to September 2019,randomized controlled trials (RCTs)about the efficacy and safety of Peficitinib (trial group )versus placebo (control group )in the treatment of RA were collected. The risk of bias assessment tool provided in Cochrane System Evaluator Manual 5.1.0 was used to evaluate the quality after data extracted from clinical studies which met the inclusion criteria. Meta-analysis of the efficacy [the proportion of patients who met the American College of Rheumatology 20% improvement criteria (ACR20),ACR50,ACR70,the proportion of the patients with 28 joint disease activity index <2.6 calculated by erythrocyte sedimentation rate (DAS28-ESR<2.6),the proportion of patients with 28 joint disease activity index <2.6 calculated by C-reactive protein (DAS28-CRP<2.6),etc.] and safety(incidence of total ADR )was performed by using Stata 16 statistical software. RESULTS :Totally 5 RCTs were included , 药学。E-mail:hyl3160131@163.com 5.11),P<0.001],150 mg[RR=3.52,95%CI(1.78,6.96),P< 0.001]},ACR70{total [RR =2.51,95%CI(1.52,4.14),P<0.001],100 mg[RR=3.50,95%CI(1.62,7.58),P=0.001],150 mg [RR=4.59,95%CI(1.47,14.30),P=0.009]},DAS28-ESR<2.6{total [RR =4.83,95%CI(3.20,7.28),P<0.001],100 mg[RR= 5.37,95%CI(2.68,10.77),P<0.001],150 mg[RR=7.44,95%CI(3.78,14.65),P<0.001]} and DAS 28-CRP<2.6{total [RR =3.41, 95%CI(2.65,4.39),P<0.001],100 mg[RR=4.00,95%CI(2.67,5.99),P<0.001],150 mg[RR=4.45,95%CI(2.99,6.63),P< 0.001]} in trial group were significantly higher than control group ,with statistical significance. In term of safety ,there was no statistical significance in the incidence of total ADR [RR =1.05,95% CI(0.94,1.16),P=0.395] between 2 groups. CONCLUSIONS:For the treatment of RA ,100 mg or 150 mg peficitinib once per day is superior to placebo in terms of ACR 20, ACR50 and ACR 70,DAS28-ESR<2.6,DAS28-CRP<2.6; the adverse events are mild and tolerable and it may be a new treatment option for RA.
10.Efficacy and Safety of Guselkumab in the Treatment of Moderate-to-severe Plaque Psoriasis :A Systematic Re- view
Xin LIU ; Xiaoyan ZHONG ; Changjing XU ; Danjie ZHAO ; Qingze FAN ; Bin YU ; Yilan HUANG
China Pharmacy 2020;31(10):1266-1271
OBJECTIVE:To systematically evaluate the efficacy and safety of guselkumab in the treatment of moderate-to- severe plaque psoriasis ,and to provide evidence-based reference for the clinical treatment. METHODS :Retrieved from PubMed , Embase,Cochrane Library ,CNKI,VIP,Wanfang database during inception to Oct. 2019,randomized controlled trials (RCTs) about guselkumab versus placebo/positive control in the treatment of moderate-to-severe plaque psoriasis were collected. After literature screening and data extraction ,quality evaluation was performed by using the bias risk evaluation tool recommended by the Cochrane System evaluator manual 5.1.0. Meta-analysis was performed by using Stata 16.0 software. RESULTS :Eight RCTs with a total of 3 488 patients were included. The results of Meta-analysis indicated that the proportion of patients who achieved 90% reduction or more from baseline of psoriasis area and severity index (PASI)in guselkumab group was significantly higher than that placebo group [RR =26.72,95%CI(15.98,44.70),P<0.001],adaliumumab group [RR =1.45,95%CI(1.32,1.59), P<0.001] and secukinumab group (P<0.000 1). The proportion of patients with Investigator ’s Global Assessment (IGA)score of 0 or 1 in guselkumab group was significantly better than placebo group [RR =11.15,95% CI(8.22,15.14),P<0.001] and adaliumumab group [RR =1.27,95%CI(1.19,1.35),P<0.001]. The proportion of patients with IGA score of 0,the proportion of patients who achieved 75% reduction or more from baseline of PASI ,dermatology life qu ality index score of 0 or 1 in guselkumab group were signifi cantly superior than placebo group and adaliumumab gr oup,the proportion of patients who achieved 100% reduction from baseline of PASI in guselkumab group Lewx- was significantly superior than placebo group (P<0.05), inn@outlook.com there was no significant difference compared with adaliumumab group (P>0.05). There was no statistical significance in the proportion of patients with IGA score of and other secondary outcome indicators between guselkumab and secukinumab group (P>0.05). In the safety indicators as total incidence rate of ADR ,rate of withdrawl due to ADR ,etc. ,there was no statistical significance between guselkumab and placebo/ adalimumab groups (P>0.05). CONCLUSIONS :Guselkumab is superior to placebo ,adaliumumab and secukinumab in improving the symptoms of moderate-to-severe plaque psoriasis with good safety .


Result Analysis
Print
Save
E-mail